Littleton, CO, August 17, 2011 --(PR.com
)-- DUX4 is a transcriptional activator of PITX1, whose expression is epigenetically suppressed in differentiated tissues. DUX4 defects are suspected to cause facioscapulohumeral dystrophy (FSHD), a degenerative skeletal muscle disease and one of the most common muscular dystrophies. In FSHD individuals, the expression of the DUX4 is not completely suppressed in skeletal muscle. Novus’ new DUX4 antibody (Catalog Number NBP1-49552) is useful for highly specific Western blot, immunohistochemistry, and immunofluorescence staining on human samples.
The DUX4 antibody is highly characterized and extremely useful tool for transcription regulation, neuroscience and neurodegeneration research. They also offer DUX4 RNAi and recombinant protein for use as controls.
About Novus Biologicals (www.novusbio.com)
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.